Titan pharmaceuticals inc (TTNP)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Sep'10Jun'10
Revenues:
License revenue

-

-

-

-

-

-

-

-

1,064

-

40

77

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total revenues

1,336

1,217

947

502

945

2,300

1,650

2,668

0

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Operating expenses:
Grant revenue

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

License revenue

-

-

-

-

-

-

-

-

-

-

-

-

40

-

26

15,004

0

0

0

760

911

913

911

911

911

911

2,198

2,198

3,750

-

0

0

-

-

-

-

-

1

-

Royalty revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

1,424

934

1,228

1,360

1,228

1,294

973

602

716

396

55

Grant revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

42

119

39

93

232

3,203

1,287

Total revenues

-

-

-

-

-

-

-

-

1,064

58

40

77

40

35

26

15,004

0

0

0

760

911

913

911

911

911

911

2,198

2,198

5,174

3,259

1,228

1,360

1,270

1,413

1,012

695

948

3,600

1,342

Cost of goods sold

171

550

188

246

304

290

178

70

0

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Research and development

2,277

1,872

1,619

1,907

1,844

1,855

1,910

1,857

1,856

2,307

2,714

2,501

2,126

2,090

1,590

1,746

700

1,135

1,010

1,099

1,431

1,596

782

748

949

929

1,679

1,789

3,912

2,573

2,995

1,973

3,069

1,291

2,230

3,947

3,738

3,044

2,056

Selling, general and administrative

3,114

2,589

3,023

3,231

3,082

2,357

1,514

1,380

1,615

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total operating expenses

5,562

5,011

4,830

5,384

5,230

-

3,602

3,307

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

General and administrative

-

-

-

-

-

-

-

-

-

-

1,396

1,197

1,351

-

1,052

1,214

1,131

1,115

792

753

1,095

570

867

713

896

624

647

701

1,091

1,128

890

1,126

1,733

888

739

948

793

691

1,012

Total operating expenses

-

-

-

-

-

-

-

-

3,471

3,432

4,110

3,698

3,477

3,289

2,642

2,960

1,831

2,250

1,802

1,852

2,526

2,166

1,649

1,461

1,845

1,553

2,326

2,490

5,003

3,701

3,885

3,099

4,802

2,179

2,969

4,895

4,531

3,735

3,068

Loss from operations

-4,226

-3,794

-3,883

-4,882

-4,285

-3,266

-1,952

-639

-2,407

-3,374

-4,070

-3,621

-3,437

-3,254

-2,616

12,044

-1,831

-2,250

-1,802

-1,092

-1,615

-1,253

-738

-550

-934

-642

-128

-292

171

-442

-2,657

-1,739

-3,532

-766

-1,957

-4,200

-3,583

-135

-1,726

Other expense:
Interest expense, net

-222

-230

-238

-253

-246

-232

-227

-230

-198

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1

0

0

-1,569

233

-1,634

-1,897

-1,563

-3,192

-1,194

-1,113

-931

-124

-120

Non-cash gain on changes in fair value

-

-

-

-

-

-

-

-

-

-

2

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash loss on changes in the fair value of warrants

923

-

-1,041

-

0

-

-141

-

-

-

-

-190

-422

-936

5

110

-4

46

2

1,185

3,279

-770

-1,461

284

864

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other income (expense), net

-213

14

-14

3

14

135

-7

0

0

78

-123

-20

10

-46

1

-6

-19

2

-3

-4

-3

10

-7

-8

-6

-

-

-

-

5,268

-5,356

-43

-52

-

-

-

2

-

-

Non-cash gain on debt extinguishment

-

-

291

-65

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other income (expense), net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

7

6

-10,444

-

-

-

-

-

43

46

-

125

-

Non-cash gain (loss) on changes in the fair value of warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-1,010

5,362

-3,045

-

-3,673

1,955

-16

-

2,390

-1,630

-

-

-

Other expense, net

-1,358

-147

1,080

-315

-232

-238

-93

-230

-198

-286

-121

170

432

927

-4

-116

-15

-44

-5

-1,189

-3,282

780

1,454

-292

-870

433

-1,017

5,356

5,830

-5,145

-49

15

-1,631

-2,132

1,153

-2,789

-929

-249

-120

Net loss and comprehensive loss

-5,584

-

-

-

-4,517

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss and comprehensive loss

-

-

-2,803

-5,197

-

-

-2,045

-869

-2,605

-3,660

-4,191

-3,451

-3,005

-2,327

-2,620

11,928

-1,846

-

-1,807

-2,281

-

-

-

-

-

-

-

-

-

-

-8,013

-1,724

-5,163

-

-

-

-4,512

-384

-1,846

Deemed dividend on trigger of down round provision

-

-

0

-

-

-

285

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss and comprehensive loss attributable to common stockholders

-

-

-2,803

-

-

-

-2,330

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss attributable to common stockholders

-

-

-2,803

-

-

-

-2,330

-

-

-

-4,191

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss applicable to common stockholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-4,897

-

716

-842

-1,804

-209

-1,145

5,064

6,001

-

-

-

-

-

-

-

-

-

-

Basic net loss per share

-

-

-0.18

-

-

-

-0.64

-

-

-3.55

-0.20

-0.16

-0.14

1.12

-0.12

0.58

-0.09

-0.12

-0.09

-0.11

-0.24

-0.15

0.04

-0.01

-0.02

0.52

-0.01

0.06

0.08

0.01

-0.12

-0.03

-0.09

-

-

-

-

-

-

Diluted net loss per share

-

-

-0.18

-

-

-

-0.68

-

-

-3.69

-0.20

-0.17

-0.16

0.86

-0.12

0.55

-0.09

-0.12

-0.09

-0.11

-0.24

-0.12

-0.05

-0.01

-0.02

0.46

0.00

0.00

0.07

-0.01

-0.07

-0.06

-0.09

-

-

-

-

-

-

Weighted average shares used in computing basic net loss per common share

-

-

-

-

-

-

-

-

-

-49,471

21,204

21,204

21,199

-47,939

21,199

20,508

20,060

20,061

20,060

20,060

20,031

-125,881

16,182

88,998

88,929

-183,619

82,544

82,527

78,256

74,826

66,839

64,984

59,387

-

-

-

-

-

-

Weighted average shares used in computing diluted net loss per common share

-

-

-

-

-

-

-

-

-

-49,632

21,204

21,204

21,376

-49,169

21,199

21,878

20,400

20,023

20,060

20,073

20,056

-125,936

16,249

88,998

88,929

-191,749

82,544

82,559

86,762

74,826

66,839

64,984

59,387

-

-

-

-

-

-

Net loss and comprehensive loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-804

-6,989

-

-

-

Basic and diluted net loss per common share

-0.07

-

-

-0.38

-0.34

-

-

-0.25

-0.74

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.01

-0.12

-0.08

-0.01

-0.03

Weighted average shares used in computing basic and diluted net loss per common share

82,641

-

15,517

13,576

13,217

-

3,650

3,534

3,534

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Weighted average shares used in computing basic and diluted net loss per common share

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

59,386

59,276

59,248

59,248

59,248

License revenue
Total revenues

0

2

0

0

313

-

1,406

2,593

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Product revenue
Total revenues

210

195

190

304

317

-

244

75

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Grant revenue
Total revenues

1,126

1,020

757

198

315

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-